These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3301260)

  • 1. [Treatment of type II diabetes using homologous intermediate-acting insulin combinations. Comparison of the effectiveness of 5 commonly used preparations].
    Haupt E; Hoppe FU; Rudolf R; Bamberg E
    Dtsch Med Wochenschr; 1987 Jul; 112(31-32):1209-12. PubMed ID: 3301260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the effects of protamine-bound NPH porcine insulin and NPH human insulin in type 1 and 2 diabetes].
    Renner R; Vocke K; Hepp KD
    Dtsch Med Wochenschr; 1986 Aug; 111(35):1316-20. PubMed ID: 3743441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
    Goicolea I; Quiroga A; Vazquez JA
    Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Are des-Phe-insulin-containing insulin combinations preferable to regular trade preparations?].
    Sachse G; Federlin K
    Med Klin; 1981 May; 76(11):319-23. PubMed ID: 7017364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term therapy with human insulin. Clinical experiences].
    Sachse G; Mäser E; Federlin K
    Dtsch Med Wochenschr; 1985 Mar; 110(11):403-6. PubMed ID: 3884307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
    Saner B; Fankhauser S
    Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical use of NPH insulin (author's transl)].
    Roesner M; Sauer H
    Dtsch Med Wochenschr; 1976 Jun; 101(23):886-9. PubMed ID: 1269430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW; Teller WM; Heinze E
    Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of an intermediate action insulin in diabetics non-respondents to oral treatment].
    Díaz C J; Moneada V S; Orriols W M; Durruty A P
    Rev Med Chil; 2007 Oct; 135(10):1358-60. PubMed ID: 18180847
    [No Abstract]   [Full Text] [Related]  

  • 16. Miscibility of short- and intermediate-acting insulins.
    Heine RJ
    Neth J Med; 1985; 28 Suppl 1():12-4. PubMed ID: 3892332
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin glargine (Lantus).
    Owens DR; Griffiths S
    Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of highly purified Iletin-II-type porcine insulins and human insulin preparations in clinical practice].
    Petunina NA; Balabolkin MI; Mkrtumian AM; Sergeev AV; Nedosugova LV
    Ter Arkh; 1993; 65(10):29-31. PubMed ID: 8296229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.